Oncology Business Management

The FDA has assigned a priority review designation to bevacizumab (Avastin) plus chemotherapy as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

As the use of electronic patient portals grows, a new study examines the use of these portals by cancer patients, extending the doctor-patient relationship to new boundaries.

A pilot program that paid oncologists upfront for the patient's full treatment program regardless of the drugs administered resulted in a 34% reduction in medical costs.

Channel dynamics are changing for physician-administered infusible drugs, with implications for practice economics, payer utilization management, site of care, and availability of data for manufacturers.

With the uncertainty that accompanies health reform, a safe and secure alignment that integrates oncologists with a hospital or academic medical center can be seductive.

A bill has been proposed in the House of Representatives seeking to ease some of the financial burdens placed on community oncologists by the sequestration. But does it go far enough?

The FDA has granted a breakthrough therapy designation to blinatumomab for the treatment of adult patients with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)